linjc16/ctgov huggingface dataset:
Kinesio Taping and Calf Muscle Fatigue

Study Overview
=================
Brief Summary
-----------------
Muscle fatigue results in decreased ability in muscles to generate force. Kinesio Tape may reverse the adverse effects of fatigue. Thus this study will examine the acute effects of Kinesio tape on muscle fatigue.

Detailed Description
-----------------
The participants will be divided into three groups; 1. Experimental group: Kinesio tape with 50% tension will be applied; 2. Sham group: Kinesio tape without any tension will be applied; 3. Placebo group: Rigid tape without any tension will be applied.

Official Title
-----------------
Effects of Kinesio Taping on Calf Muscle Fatigue in Collegiate Female Athletes

Conditions
-----------------
Fatigue

Intervention / Treatment
-----------------
* Other: Kinesio Taping under tension.
* Other: Kinesio Tape without tension
* Other: Rigid Taping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy cooperative individuals. Female athletes who were engaged in training at least 3 times a week. The subject should perform a minimum of 23 hell raises. Exclusion Criteria: Musculoskeletal injuries, cardio-pulmonary vestibular and neurological complication and systemic disorder. Consumption of any pre-workout supplement in the last 6 months. Involvement in any other training program.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Three-arm parallel group
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental Group<br>Participants will be applied Kinesio tape with 50% tension. | Other: Kinesio Taping under tension.<br>* Kinesio tape will be applied to participants under tension.<br>|
| Sham Comparator: Sham Group<br>Participants will be applied Kinesio tape without any tension. | Other: Kinesio Tape without tension<br>* Kinesio tape will be applied to participants without any tension.<br>|
| Placebo Comparator: Placebo Group<br>Participants will be applied rigid tape without any tension | Other: Rigid Taping<br>* Rigid Taping will be applied.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of heel raises | Participants will have to perform heel raises in standing position untill thay are fatigued. | 1 week. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Calf Muscle, Kinesio tape, Muscle fatigue, Heel raises
Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the prevalence of malnutrition and/or sarcopenia at admission to the hospital in older adults.

Detailed Description
-----------------
The primary outcome of this study is to determine the prevalence of malnutrition and/or sarcopenia at admission to the hospital in older adults. The secondary outcome is to assess the relationship between malnutrition/sarcopenia status and length of stay, comorbidity load, polypharmacy, and 30-day readmission.

Official Title
-----------------
Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission

Conditions
-----------------
Malnutrition, Sarcopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to the UTMB ACE unit Aged 65 years or older Able to consent to participate in study (alert and oriented x3) Exclusion Criteria: Because this study aims to determine prevalence of malnutrition and/or sarcopenia at admission to the hospital, patients will be excluded if study measures are not able to be taken within 72 hours of admission.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Malnutrition | malnutrition measured with questionnaires | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of sarcopenia | Sarcopenia defined using the EWGSOP or IWGS or FNIH criteria | baseline |
Respiratory Physiotherapy in Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
This study aimed to evaluate the effect of respiratory physiotherapy that is breathing exercise during weaning on ventilated patients in ICU.

Detailed Description
-----------------
Respiratory physiotherapy is a treatment approach to increase ventilation and function in patients with acute and chronic problems and to reduce respiratory work and dyspnea.Airway cleaning techniques, lung volume-enhancing approaches, thoracic mobilization, positioning, breathing exercises and inhalation therapy are among the strategies used. In patients with invasive MV support, respiratory physiotherapy is the position, tracheal cleaning and inhalation therapy when necessary. But breathing exercises are not indicated in the acute phase. In the process of weaning, inspiratory muscle training and breathing exercises can be used.

Official Title
-----------------
the Effect of Respiratory Physiotherapy to Weaning in Invasive Mechanical Ventilation

Conditions
-----------------
Respiratory Failure

Intervention / Treatment
-----------------
* Procedure: breath exercises


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: weaning period of patients in invasive mechanical ventilation patients in stable hemodynamic parameters Exclusion Criteria: under 18 years old pregnant non-cooperative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SPT<br> | Procedure: breath exercises<br>* diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weaning success | effect of respiratory physiotherapy as diaphragmatic exercise of weaning | 1-7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance | effect of diaphragmatic exercise on compliance, diaphragmatic movement | 1-7 days | 
| diaphragmatic movement | effect of diaphragmatic exercise on diaphragmatic movement | 1-7 days | 
| arterial blood gas | effect of diaphragmatic exercise on diaphragmatic movement | 1-7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
respiratory physiotherapy
Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)

Study Overview
=================
Brief Summary
-----------------
The main hypothesis is that PET-CT will be a valuable diagnostic tool in diagnosing and evaluating treatment for IBD.

Official Title
-----------------
Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Procedure: PET-CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with either Crohn's disease or ulcerative colitis whose disease is flaring Exclusion Criteria: Indeterminate diagnosis, pregnant, breastfeeding, or other contraindication to PET-CT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: PET-CT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Does this technique provide an accurate assessment of disease inflammation compared to standard clinical markers? |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Does this technique provide additional information for practitioners on extent of disease? |  |  |
Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate

Study Overview
=================
Brief Summary
-----------------
Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.

Conditions
-----------------
Benign Prostatic Hyperplasia, Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to National Cheng Kung University Hospital Urology during the study Older than 20 years old Agree to participate this study Receiving transurethral resection of the prostate for benign prostatic hyperplasia or prostate cancer Exclusion Criteria: Poor expression ability and without close care givers to answer questions

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Non anticoagulant and/or antiplatelet users. | |
| B<br>Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods. | |
| C<br>Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative blood transfusion |  | in 1 week after surgery | 
| Bladder clots |  | in 10 days after surgery | 
| Hematuria |  | in 10 days after surgery | 
| Urine tract infection |  | in 10 days after surgery | 
| Duration of catheter |  | in 10 days after surgery | 
| Duration of hospitalization |  | in 1 week after surgery | 
| Cardiovascular event |  | In 28 days after surgery | 
| Major bleeding |  | In 28 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transurethral resection of the prostate, Anticoagulants, Platelet aggregation inhibitors
The Parkinson's Genetic Research Study

Study Overview
=================
Brief Summary
-----------------
The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.

Detailed Description
-----------------
PaGeR is focusing on families in which two or more people have been diagnosed with PD. Past research suggests that such multiplex families might hold the key to the discovery of new PD genes. To take part in PaGeR, participants will be asked to complete a questionnaire and to undergo an interview, a neurological exam, a short memory test, and a blood draw. Enrollment in the study usually takes between one and two hours. There is no cost to participate, and all study information is kept strictly confidential. There are a number of designated sites across the country where families can enroll. However, for family members who are unable to travel to one of these sites, other arrangements can be made.

Official Title
-----------------
The Parkinson's Genetic Research Study (PaGeR)

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years of age Member of a family in which there are two or more living individuals who have been diagnosed with Parkinson's disease Exclusion Criteria: Under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Has a diagnosis of Parkinson's disease | |
| Control<br>No diagnosis of Parkinson's disease | |
| Family Member<br>Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's Disease, Genetics, Family Research, Hereditary Neurodegenerative Diseases
Effect of Rosiglitazone

Study Overview
=================
Brief Summary
-----------------
To evaluate : acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose) on insulin secretion and insulin sensitivity in 12 healthy male subjects.

Official Title
-----------------
Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: rosiglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI between 18.0 and 24.0 Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rosiglitazone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin clearance |  |  | 
| basal glycemia and insulinemia |  |  | 
| tolerance |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rosiglitazone, insulin secretion, clinical trial, healthy, persons
Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether propolis is effective in the treatment and prevention of radiotherapy induced oral mucositis.

Detailed Description
-----------------
Patients with head and neck malignancy with inclusion criteria randomly divide in 2 groups and take the intervention.

Official Title
-----------------
Phase I Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers

Conditions
-----------------
Radiation-induced Mucositis of Oral Mucous Membranes

Intervention / Treatment
-----------------
* Drug: propolis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - age >15 need of radiotherapy at least half of the mouth in the field of radiation dose 50 -70 Gy head & neck malignancy Exclusion Criteria: systemic disease FBS > 150 WBC > 3000 history of radiotherapy need of chemotherapy systemic disease

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo mouth wash<br>10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session | Drug: propolis<br>* 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow<br>|
| Active Comparator: propolis<br>10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session | Drug: propolis<br>* 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NCI.CTC Scale | we use NCI-CTC scale for patients in 2 groups to assess effect of propolis mouth wash on prevention and treatment of mucositis in patients under radiotherapy.We measured signs(size and sypmtoms) of mucositis by NCI-CTC scale and also we assessed the onset of the mucositis to describe the prevention efficacy of propolis. | 9 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hyposalivation scale | we use a scale for patients in 2 groups to assess effect of propolis maouth wash on subjective xerostomy and signs of candidiasis in patiants under radiotherapy | 9 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propolis, mucositis, radiotherapy, cancer
Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Vildagliptin 100 mg qd
* Drug: Metformin 1500 mg daily


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 65 years to the upper age limit recommended by local prescribing information for metformin Drug naive patients with type 2 diabetes. Body mass index (BMI) in the range of 22-40 kg/m2. HbA1c in the range of 7 to 9% inclusive FPG <270 mg/dL (15 mmol/L) Exclusion Criteria: A history of type 1 diabetes Evidence of significant diabetic complications Treatment with insulin or any other oral antidiabetic agents Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vildagliptin<br> | Drug: Vildagliptin 100 mg qd<br> <br> |
| Active Comparator: Metformin<br> | Drug: Metformin 1500 mg daily<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in HbA1c |  | after 24 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event profile |  | after 24 weeks of treatment | 
| Gastrointestinal tolerability |  | after 24 weeks of treatment | 
| Patients with endpoint HbA1c <7% and patients with reduction in HbA1c > 0.7% |  | after 24 weeks of treatment | 
| Change from baseline in fasting plasma glucose |  | after 24 weeks of treatment | 
| Change from baseline in body weight |  | after 24 weeks of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes, vildagliptin, hemoglobin A1c, metformin